Cooper Companies (NASDAQ:COO) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Cooper Companies (NASDAQ:COO) had its price objective boosted by research analysts at Wells Fargo & Company from $72.00 to $82.00 in a report released on Friday,Benzinga reports. The brokerage presently has an “equal weight” rating on the medical device company’s stock. Wells Fargo & Company‘s target price points to a potential upside of 0.42% from the stock’s current price.

A number of other research analysts have also commented on the company. KeyCorp restated a “sector weight” rating on shares of Cooper Companies in a research note on Friday. Needham & Company LLC reissued a “buy” rating and issued a $100.00 price target (up previously from $94.00) on shares of Cooper Companies in a report on Friday. Piper Sandler restated an “overweight” rating and issued a $94.00 price objective on shares of Cooper Companies in a research note on Friday. Robert W. Baird lifted their target price on shares of Cooper Companies from $85.00 to $98.00 and gave the company an “outperform” rating in a research report on Friday. Finally, Barclays started coverage on shares of Cooper Companies in a research note on Monday, October 13th. They issued an “overweight” rating and a $85.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $90.31.

Cooper Companies Stock Performance

Shares of NASDAQ:COO traded up $4.63 on Friday, hitting $81.66. 3,692,179 shares of the company were exchanged, compared to its average volume of 2,413,876. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.24 and a current ratio of 2.12. The company’s 50 day moving average price is $72.01 and its two-hundred day moving average price is $71.74. Cooper Companies has a one year low of $61.78 and a one year high of $101.53. The firm has a market capitalization of $16.24 billion, a price-to-earnings ratio of 40.18, a PEG ratio of 1.87 and a beta of 1.05.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.11 by $0.04. The firm had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The company’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the company posted $1.04 earnings per share. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. Research analysts expect that Cooper Companies will post 3.98 earnings per share for the current year.

Cooper Companies announced that its Board of Directors has authorized a stock buyback program on Wednesday, September 17th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical device company to purchase up to 15.4% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s management believes its shares are undervalued.

Insider Buying and Selling at Cooper Companies

In other news, Director Lawrence Erik Kurzius bought 2,000 shares of the business’s stock in a transaction dated Monday, September 29th. The stock was bought at an average price of $68.39 per share, for a total transaction of $136,780.00. Following the completion of the purchase, the director owned 5,777 shares of the company’s stock, valued at approximately $395,089.03. The trade was a 52.95% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.98% of the company’s stock.

Institutional Investors Weigh In On Cooper Companies

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bell Investment Advisors Inc boosted its stake in Cooper Companies by 106.3% in the third quarter. Bell Investment Advisors Inc now owns 425 shares of the medical device company’s stock worth $29,000 after purchasing an additional 219 shares in the last quarter. Zions Bancorporation National Association UT bought a new position in shares of Cooper Companies in the first quarter valued at about $33,000. J.Safra Asset Management Corp raised its holdings in shares of Cooper Companies by 204.8% in the second quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock valued at $36,000 after buying an additional 340 shares during the last quarter. CYBER HORNET ETFs LLC acquired a new position in Cooper Companies during the 2nd quarter worth about $36,000. Finally, GKV Capital Management Co. Inc. bought a new stake in Cooper Companies during the 1st quarter worth about $40,000. 24.39% of the stock is owned by institutional investors and hedge funds.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.